Estrella Immunopharma, Inc. (ESLA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US2975841048
Estrella Immunopharma, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -13.06 m USD |
| EBIT | -13.06 m USD |
| Net income | -13.06 m USD |
| Diluted EPS – continuing operations | -0.35 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
More stocks
- DESTINATION XL GROUP, INC. (DXLG)
- All In FutureTech Alliance, Inc. (AIFA)
- CREDITRISKMONITOR COM INC (CRMZ)
- CEL SCI CORP (CVM)
- FiEE, Inc. (FIEE)
- MicroAlgo Inc. (MLGO)
- Transcode Therapeutics, Inc. (RNAZ)
- Helio Corp /FL/ (HLEO)
- GEX MANAGEMENT, INC. (GXXM)
- CHINA PHARMA HOLDINGS, INC. (CPHI)
- Gouverneur Bancorp, Inc./MD/ (GOVB)
- Caro Holdings Inc. (CAHO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.